000130047 001__ 130047
000130047 005__ 20240118092027.0
000130047 0247_ $$2doi$$a10.3390/ijms14047716
000130047 0248_ $$2sideral$$a81812
000130047 037__ $$aART-2013-81812
000130047 041__ $$aeng
000130047 100__ $$0(orcid)0000-0002-8100-5596$$aMartínez-Beamonte, R.$$uUniversidad de Zaragoza
000130047 245__ $$aSphingomyelin in High-Density Lipoproteins: Structural Role and Biological Function
000130047 260__ $$c2013
000130047 5060_ $$aAccess copy available to the general public$$fUnrestricted
000130047 5203_ $$aHigh-density lipoprotein (HDL) levels are an inverse risk factor for cardiovascular diseases, and sphingomyelin (SM) is the second most abundant phospholipid component and the major sphingolipid in HDL. Considering the marked presence of SM, the present review has focused on the current knowledge about this phospholipid by addressing its variable distribution among HDL lipoparticles, how they acquire this phospholipid, and the important role that SM plays in regulating their fluidity and cholesterol efflux from different cells. In addition, plasma enzymes involved in HDL metabolism such as lecithin–cholesterol acyltransferase or phospholipid transfer protein are inhibited by HDL SM content. Likewise, HDL SM levels are influenced by dietary maneuvers (source of protein or fat), drugs (statins or diuretics) and modified in diseases such as diabetes, renal failure or Niemann–Pick disease. Furthermore, increased levels of HDL SM have been shown to be an inverse risk factor for coronary heart disease. The complexity of SM species, described using new lipidomic methodologies, and their distribution in different HDL particles under many experimental conditions are promising avenues for further research in the future.
000130047 536__ $$9info:eu-repo/grantAgreement/ES/CICYT-FEDER/SAF 2010-14958$$9info:eu-repo/grantAgreement/ES/DGA-FSE/B69
000130047 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000130047 590__ $$a2.339$$b2013
000130047 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b52 / 145 = 0.359$$c2013$$dQ2$$eT2
000130047 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000130047 700__ $$0(orcid)0000-0001-9578-6525$$aLou-Bonafonte, J.$$uUniversidad de Zaragoza
000130047 700__ $$aMartínez-Gracia, M. V.
000130047 700__ $$0(orcid)0000-0002-8251-8457$$aOsada, J.$$uUniversidad de Zaragoza
000130047 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000130047 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000130047 773__ $$g14, 4 (2013), 7716-7741$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000130047 8564_ $$s820463$$uhttps://zaguan.unizar.es/record/130047/files/texto_completo.pdf$$yVersión publicada
000130047 8564_ $$s1999264$$uhttps://zaguan.unizar.es/record/130047/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130047 909CO $$ooai:zaguan.unizar.es:130047$$particulos$$pdriver
000130047 951__ $$a2024-01-18-09:06:58
000130047 980__ $$aARTICLE